Literature DB >> 25446328

Cross matching observations on toxicological and clinical data for the assessment of tolerability and safety of Ginkgo biloba leaf extract.

Tuula Heinonen1, Wilhelm Gaus2.   

Abstract

Ginkgo biloba is one of the most widely used herbal remedies in Europe and the US. It may be purchased in different types of formulations, but most of the clinical studies have been performed with the controlled G. biloba extract EGb761(®). Indications include Alzheimers disease, cardiovascular disease, dementia, memory loss, and cerebral ischemia. The pharmacological modes of action cover antioxidant effects, radical scavenging, inhibition of platelet activating factor, alterations in membrane fluidity (signal transduction), and inhibition of glucocorticoid synthesis. Due to the widespread and long-term use of G. biloba - about a million doses of EGb761(®) are sold per day - tolerability and safety are a crucial issue. Based on broad and long-term clinical use of G. biloba extracts, it is regarded as well tolerated in man. Cross matching, a tool we introduced, combines different fields of knowledge and types of data to a consolidated result. In this article, we combine toxicological and clinical data and utilize other sources of information to assess tolerability and safety of G. biloba. It is well known that because of biological differences between animals and man or even between animal species, animal experiments do not necessarily mimic the effects in humans. Therefore, for adequate risk assessment, the relevance of non-clinical toxicological findings should be correlated with human data. The cross matching of toxicological data and results from clinical studies is possible because many toxicological and clinical studies are available on G. biloba. We give an in depth analysis of the modes of action in animals and describe toxicological studies with regard to metabolism, pharmacokinetics, genotoxicity, as well as carcinogenicity (e.g., the Technical Report TR 578 of the US National Toxicology Program). In addition, 75 clinical trials with high methodological quality are summarized. They included a total of 7115 patients treated with G. biloba. Based on this extensive amount of information, the broad variety of investigations, and their accordance we conclude that G. biloba extract is well tolerated and safe for humans.
Copyright © 2014 The Authors. Published by Elsevier Ireland Ltd.. All rights reserved.

Entities:  

Keywords:  Adverse drug reaction; Carcinogenicity; Clinical studies; Cross matching; EGb761(®), CAS 122933-57-7; Ginkgo biloba

Mesh:

Substances:

Year:  2014        PMID: 25446328     DOI: 10.1016/j.tox.2014.10.013

Source DB:  PubMed          Journal:  Toxicology        ISSN: 0300-483X            Impact factor:   4.221


  15 in total

1.  A 90 day oral toxicity study of blueberry polyphenols in ovariectomized sprague-dawley rats.

Authors:  Dennis P Cladis; Shiyu Li; Lavanya Reddivari; Abigail Cox; Mario G Ferruzzi; Connie M Weaver
Journal:  Food Chem Toxicol       Date:  2020-03-09       Impact factor: 6.023

2.  Natural Compounds as Occult Ototoxins? Ginkgo biloba Flavonoids Moderately Damage Lateral Line Hair Cells.

Authors:  Sarah Neveux; Nicole K Smith; Anna Roche; Bruce E Blough; Wimal Pathmasiri; Allison B Coffin
Journal:  J Assoc Res Otolaryngol       Date:  2016-11-28

3.  Ginkgo biloba Extract (GbE) Restores Serotonin and Leptin Receptor Levels and Plays an Antioxidative Role in the Hippocampus of Ovariectomized Rats.

Authors:  Meira Maria Forcelini Machado; Renata Mancini Banin; Fernanda Malanconi Thomaz; Iracema Senna de Andrade; Valter Tadeu Boldarine; Jéssica de Souza Figueiredo; Bruna Kelly Sousa Hirata; Lila Missae Oyama; João Henrique Ghilardi Lago; Eliane Beraldi Ribeiro; Mônica Marques Telles
Journal:  Mol Neurobiol       Date:  2021-01-25       Impact factor: 5.590

4.  Screening and Identifying Antioxidative Components in Ginkgo biloba Pollen by DPPH-HPLC-PAD Coupled with HPLC-ESI-MS2.

Authors:  Jiying Qiu; Xiangyan Chen; A I Netrusov; Qingxin Zhou; Danyang Guo; Xiaoyong Liu; Hailun He; Xue Xin; Yifen Wang; Leilei Chen
Journal:  PLoS One       Date:  2017-01-17       Impact factor: 3.240

Review 5.  A Balanced Risk-Benefit Analysis to Determine Human Risks Associated with Pyrrolizidine Alkaloids (PA)-The Case of Tea and Herbal Infusions.

Authors:  Michael Habs; Karin Binder; Stefan Krauss; Karolina Müller; Brigitte Ernst; Luzia Valentini; Michael Koller
Journal:  Nutrients       Date:  2017-07-07       Impact factor: 5.717

6.  Clinical and genomic safety of treatment with Ginkgo biloba L. leaf extract (IDN 5933/Ginkgoselect®Plus) in elderly: a randomised placebo-controlled clinical trial [GiBiEx].

Authors:  Stefano Bonassi; Giulia Prinzi; Palma Lamonaca; Patrizia Russo; Irene Paximadas; Giuseppe Rasoni; Raffaella Rossi; Marzia Ruggi; Salvatore Malandrino; Maria Sánchez-Flores; Vanessa Valdiglesias; Barbara Benassi; Francesca Pacchierotti; Paola Villani; Martina Panatta; Eugenia Cordelli
Journal:  BMC Complement Altern Med       Date:  2018-01-22       Impact factor: 3.659

7.  Ginkgo biloba special extract LI 1370 improves dual-task walking in patients with MCI: a randomised, double-blind, placebo-controlled exploratory study.

Authors:  Yves J Gschwind; Stephanie A Bridenbaugh; Sarah Reinhard; Urs Granacher; Andreas U Monsch; Reto W Kressig
Journal:  Aging Clin Exp Res       Date:  2017-02-08       Impact factor: 3.636

Review 8.  Therapeutic Effects of Traditional Chinese Medicine on Spinal Cord Injury: A Promising Supplementary Treatment in Future.

Authors:  Qian Zhang; Hao Yang; Jing An; Rui Zhang; Bo Chen; Ding-Jun Hao
Journal:  Evid Based Complement Alternat Med       Date:  2016-03-28       Impact factor: 2.629

9.  The protective mechanism of Ginkgolides and Ginkgo flavonoids on the TNF-α induced apoptosis of rat hippocampal neurons and its mechanisms in vitro.

Authors:  Maojuan Guo; Yanrong Suo; Qing Gao; Huan Du; Wenyun Zeng; Yijing Wang; Xiantong Hu; Xijuan Jiang
Journal:  Heliyon       Date:  2015-09-21

10.  The Ginkgo biloba Extract Reverses the Renal Effects of Titanium Dioxide Nanoparticles in Adult Male Rats.

Authors:  Carlos Enrique Escárcega-González; Irma Guadalupe Reynoso-Andeola; Fernando Jaramillo-Juárez; Haydée Martínez-Ruvalcaba; Francisco A Posadas Del Rio
Journal:  Biochem Res Int       Date:  2016-03-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.